This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
قائمة المحتويات
Preface.- Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals.- Part 4. Test systems for Efficacy and Safety.- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
عن المؤلف
Dr. Ulrich Nielsch, Bayer Pharma AG, Wuppertal, Germany
Dr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, Germany
Prof. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany
المزيد من الكتب الإلكترونية من نفس المؤلف (المؤلفين) / محرر
1٬306 كتب إلكترونية في هذه الفئة
